Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F16%3A00011552" target="_blank" >RIV/00023736:_____/16:00011552 - isvavai.cz</a>
Alternative codes found
RIV/68407700:21230/16:00300243 RIV/00064165:_____/16:10329214
Result on the web
<a href="http://dx.doi.org/10.1007/s12185-016-2058-3" target="_blank" >http://dx.doi.org/10.1007/s12185-016-2058-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12185-016-2058-3" target="_blank" >10.1007/s12185-016-2058-3</a>

Result language
angličtina
Original language name
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms
Original language description
Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Our data indicate that AZA treatment failure is associated with the up-regulation of ribosomal genes/pathways that are likely related to intensive proteosynthesis in proliferative/neoplastic cells of non-responders.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT14377" target="_blank" >NT14377: Prediction of the response to demethylation treatment in patients with myelodysplastic syndromes using integrative genomics</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)